2LB Late Breaking A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole
C. Ryan, A. Harzstark, L. Fong, A. Lin, C. Kilian, A. Molina, E.J. SmallVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72180-3
File:
PDF, 64 KB
english, 2008